<DOC>
	<DOCNO>NCT02385760</DOCNO>
	<brief_summary>A multi-centre , double-blind , randomize , parallel group , placebo control efficacy safety study oral CTX-4430 treatment moderate severe facial acne vulgaris .</brief_summary>
	<brief_title>CTX-4430 Treatment Moderate Severe Facial Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>1 . Must provide Informed consent . 2 . Male female age 16 44 inclusive . 3 . Moderate severe facial acne vulgaris define protocol . 1 . Positive test HIV , HBsAg , hepatitis C virus ( HCV ) . 2 . Females pregnant , lactating , plan become pregnant study . 3 . Any systemic medical condition , opinion investigator , would put participant risk participation study . 4 . Any systemic dermatologic disorder , opinion investigator interfere assessment study endpoint ( e.g . psoriasis ) . 5 . Concurrent previous use investigational drug device within 30 day prior screen . 6 . The presence acne conglobata , acne fulminans , secondary acne , nodulocystic acne . 7 . The presence know suspicious unresolved dermatological cancerous precancerous lesion . 8 . Hypersensitivity idiosyncratic reaction compound related CTX4430 component .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Facial Acne</keyword>
</DOC>